
S and which is bonded via a ring carbon atom, wherein the residue of a heterocycle is optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

m is chosen from 0, 1 and 2, wherein all numbers m are independent of each other;

wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_tH_{2t}, C_uH_{2u}, C_vH_{2v}, C_wH_{2w}, alkenyl and alkynyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

In one aspect, there is provided a compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof,



I

wherein

A is chosen from NH, O and S;

R^1 is chosen from $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_7)$-cycloalkyl-C_tH_{2t}- and Het-C_tH_{2t}-, wherein t is chosen from 0, 1, 2 and 3;

R^2 is chosen from phenyl and a residue of an aromatic, 5-membered to 6-membered monocyclic heterocycle which comprises 1, 2 or 3 identical or different ring

heteroatoms chosen from N, O and S, wherein one of the ring nitrogen atoms can carry a hydrogen atom or a substituent R^{21}, and wherein the phenyl and residue of an aromatic heterocycle are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22};

R^3 is chosen from $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_7)$-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^3 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1\text{-}C_4)$-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{31}, provided that R^3 cannot be $(C_1\text{-}C_6)$-alkyl if A is S;

R^{21} is chosen from $(C_1\text{-}C_4)$-alkyl, $(C_3\text{-}C_7)$-cycloalkyl-C_wH_{2w}- and oxy, wherein w is chosen from 0, 1 and 2;

R^{22} is chosen from halogen, hydroxy, $(C_1\text{-}C_4)$-alkyl-, $(C_1\text{-}C_4)$-alkyloxy, $(C_1\text{-}C_4)$-alkyl-$S(O)_m$-, amino, nitro, cyano, hydroxycarbonyl, $(C_1\text{-}C_4)$-alkyloxycarbonyl, aminocarbonyl, aminosulfonyl, R^{23} and R^{23}-O-;

R^{23} is a residue of a saturated 3-membered to 7-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1\text{-}C_4)$-alkyl substituent and one of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{24};

R^{24} is chosen from halogen, $(C_1\text{-}C_4)$-alkyl, hydroxy and oxo;

R^{31} is chosen from halogen, $(C_1$-$C_4)$-alkyl, $(C_3$-$C_7)$-cycloalkyl, hydroxy, $(C_1$-$C_4)$-alkyloxy, oxo, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, amino, $(C_1$-$C_4)$-alkylamino, di$((C_1$-$C_4)$-alkyl)amino, $(C_1$-$C_4)$-alkylcarbonylamino, $(C_1$-$C_4)$-alkylsulfonylamino, nitro, cyano, $(C_1$-$C_4)$-alkylcarbonyl, aminosulfonyl, $(C_1$-$C_4)$-alkylaminosulfonyl and di$((C_1$-$C_4)$-alkyl)aminosulfonyl;


Het is a residue of a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises 1 or 2 identical or different ring heteroatoms chosen from N, O and S and which is bonded via a ring carbon atom, wherein the residue of a heterocycle is optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

m is chosen from 0, 1 and 2, wherein all numbers m are independent of each other;

wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents chosen from fluorine and $(C_1$-$C_4)$-alkyl;

wherein all alkyl, C_tH_{2t}, C_uH_{2u}, C_vH_{2v}, C_wH_{2w}, alkenyl and alkynyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

In one aspect, there is provided a process for the preparation of a compound of the formula I as defined herein, comprising reacting a compound of the formula II with a compound of the formula III,



II I

wherein the groups A, R^1, R^2 and R^3 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group Alk is $(C_1$-$C_4)$-alkyl.

In one aspect, there is provided a pharmaceutical composition, comprising at least one compound of the formula I as defined herein or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In one aspect, there is provided a compound of the formula I as defined herein or a physiologically acceptable salt thereof, for use as a pharmaceutical.

In one aspect, there is provided the use of a compound of the formula I as defined herein or a physiologically acceptable salt thereof, in the manufacture of a medicament for treating wound healing disorders.

In one aspect, there is provided the use of a compound of the formula I as defined herein or a physiologically acceptable salt thereof, in the manufacture of a medicament for wound healing.

In one aspect, there is provided the use of a compound of the formula I as defined herein or a physiologically acceptable salt thereof, in the manufacture of a medicament for wound healing in diabetics.

In one aspect, there is provided the use of a compound of the formula I as defined herein or a physiologically acceptable salt thereof, in the manufacture of a medicament for treating diabetic foot syndrome.

Structural elements such as groups, substituents, hetero ring members, numbers or other features, for example alkyl groups, groups like R^{22} or R^{31}, numbers like m, u and v, which can occur several times in the compounds of the formula I, can all independently of one another have any of the indicated meanings and can in each

case be identical to or different from one another. For example, the alkyl groups in a dialkylamino group can be identical or different.

Alkyl, alkenyl and alkynyl groups can be linear, i.e. straight-chain, or branched. This also applies when they are part of other groups, for example alkyloxy groups (= alkoxy groups, alkyl-O- groups), alkyloxycarbonyl groups or alkyl-substituted amino groups, or when they are substituted. Depending on the respective definition, the number of carbon atoms in an alkyl group can be 1, 2, 3, 4, 5 or 6, or 1, 2, 3 or 4, or 1, 2 or 3. Examples of alkyl are methyl, ethyl, propyl including n-propyl and isopropyl, butyl including n-butyl, sec-butyl, isobutyl and tert-butyl, pentyl including n-pentyl, 1-methylbutyl, isopentyl, neopentyl and tert-pentyl, and hexyl including n-hexyl, 3,3-dimethylbutyl and isohexyl. Double bonds and triple bonds in alkenyl groups and alkynyl groups can be present in any positions. In one embodiment of the invention, alkenyl groups contain one double bond and alkynyl groups contain one triple bond.

wherein the groups A, R^1, R^2 and R^3 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group Alk is $(C_1$-$C_4)$-alkyl.

9. A pharmaceutical composition, comprising at least one compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, for use as a pharmaceutical.

11. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, in the manufacture of a medicament for treating wound healing disorders.

12. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, in the manufacture of a medicament for wound healing.

13. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, in the manufacture of a medicament for wound healing in diabetics.

14. Use of a compound of the formula I as claimed in any of claims 1 to 7 or a physiologically acceptable salt thereof, in the manufacture of a medicament for treating diabetic foot syndrome.